📣 VC round data is live. Check it out!
- Public Comps
- VieMed
VieMed Valuation Multiples
Discover revenue and EBITDA valuation multiples for VieMed and similar public comparables like TaiDoc Technology, Myriad Genetics, Delcath Systems, IVF hartmann and more.
VieMed Overview
About VieMed
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
Founded
2016
HQ

Employees
1.2K
Website
Financials (LTM)
EV
$373M
Valuation Multiples
Start free trialVieMed Financials
VieMed reported last 12-month revenue of $289M and EBITDA of $64M.
In the same LTM period, VieMed generated $166M in gross profit, $64M in EBITDA, and $16M in net income.
Revenue (LTM)
VieMed P&L
In the most recent fiscal year, VieMed reported revenue of $270M and EBITDA of $61M.
VieMed is profitable as of last fiscal year, with gross margin of 58%, EBITDA margin of 23%, and net margin of 6%.
Financial data powered by Morningstar, Inc.
VieMed Stock Performance
VieMed has current market cap of $370M, and enterprise value of $373M.
Market Cap Evolution
VieMed's stock price is $9.65.
VieMed share price decreased by 3.1% in the last 30 days, and increased by 45.1% in the last year.
VieMed has an EPS (earnings per share) of $0.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $373M | $370M | 0.0% | -3.1% | 10.9% | 45.1% | $0.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVieMed Valuation Multiples
VieMed trades at 1.3x EV/Revenue multiple, and 5.8x EV/EBITDA.
EV / Revenue (LTM)
VieMed Financial Valuation Multiples
As of May 26, 2026, VieMed has market cap of $370M and EV of $373M.
VieMed has a P/E ratio of 22.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified VieMed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


VieMed Margins & Growth Rates
VieMed grew revenue by 17% and EBITDA by 9% in the last fiscal year.
In the most recent fiscal year, VieMed reported gross margin of 58%, EBITDA margin of 23%, and net margin of 6%.
VieMed Margins
VieMed Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
VieMed Operational KPIs
VieMed's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
VieMed's Rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
VieMed's Rule of X is 65% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
VieMed Competitors
VieMed competitors include TaiDoc Technology, Myriad Genetics, Delcath Systems, IVF hartmann, Coltene, Universal Vision, Medipost, ClearPoint Neuro, Standard BioTools and Medios.
Most VieMed public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.8x | — | 4.0x | — | |||
| 0.5x | 0.5x | 11.5x | 11.6x | |||
| 3.4x | 3.2x | 11.6x | 17.8x | |||
| 1.2x | — | 7.4x | — | |||
| 1.4x | 1.4x | 11.7x | 11.4x | |||
| 2.4x | 2.3x | 5.2x | 5.3x | |||
| 6.6x | — | (6.2x) | — | |||
| 10.0x | 8.5x | (24.4x) | (21.6x) | |||
This data is available for Pro users. Sign up to see all VieMed competitors and their valuation data. Start Free Trial | ||||||
VieMed M&A Activity
VieMed has acquired 1 company to date.
Last acquisition by VieMed was on February 1st 2024. VieMed acquired Lehan Medical for $26M (EV/Revenue multiple of ).
Latest Acquisitions by VieMed
| Description | Lehan Medical supplies home medical equipment and pharmacy services in Owensboro, Kentucky. The store stocks mobility aids, oxygen therapy devices, and wellness products, delivering to patients in western Kentucky with insurance billing support. |
| HQ Country | |
| HQ City | DeKalb, IL |
| Deal Date | 1 Feb 2024 |
| Valuation | $26M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all VieMed acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout VieMed
| When was VieMed founded? | VieMed was founded in 2016. |
| Where is VieMed headquartered? | VieMed is headquartered in United States. |
| How many employees does VieMed have? | As of today, VieMed has over 1K employees. |
| Who is the CEO of VieMed? | VieMed's CEO is Casey Hoyt. |
| Is VieMed publicly listed? | Yes, VieMed is a public company listed on Nasdaq. |
| What is the stock symbol of VieMed? | VieMed trades under VMD ticker. |
| When did VieMed go public? | VieMed went public in 2018. |
| Who are competitors of VieMed? | VieMed main competitors include TaiDoc Technology, Myriad Genetics, Delcath Systems, IVF hartmann, Coltene, Universal Vision, Medipost, ClearPoint Neuro, Standard BioTools, Medios. |
| What is the current market cap of VieMed? | VieMed's current market cap is $370M. |
| What is the current revenue of VieMed? | VieMed's last 12 months revenue is $289M. |
| What is the current revenue growth of VieMed? | VieMed revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of VieMed? | Current revenue multiple of VieMed is 1.3x. |
| Is VieMed profitable? | Yes, VieMed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of VieMed? | VieMed's last 12 months EBITDA is $64M. |
| What is VieMed's EBITDA margin? | VieMed's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of VieMed? | Current EBITDA multiple of VieMed is 5.8x. |
| How many companies VieMed has acquired to date? | As of May 2026, VieMed has acquired 1 company. |
| What was the largest acquisition by VieMed? | $26M acquisition of Lehan Medical on 1st February 2024 was the largest M&A VieMed has done to date. |
| What companies VieMed acquired? | VieMed acquired Lehan Medical. |
| In how many companies VieMed has invested to date? | VieMed hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to VieMed
Lists including VieMed
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
